D
Delin Kong
Researcher at Northeast Forestry University
Publications - 6
Citations - 109
Delin Kong is an academic researcher from Northeast Forestry University. The author has contributed to research in topics: Myocyte & Mitochondrion. The author has an hindex of 5, co-authored 6 publications receiving 70 citations.
Papers
More filters
Journal ArticleDOI
MiR-17 and miR-19 cooperatively promote skeletal muscle cell differentiation
TL;DR: It is shown thatmiR-17 and miR-20a could effectively promote the differentiation of both C2C12 myoblasts and primary bovine satellite cells and the wound healing abilities of the two miRNAs are demonstrated by co-injecting the lentiviral shRNAs of miR -17 andMiR-19 into mouse tibialis anterior muscles.
Journal ArticleDOI
MiR-7 mediates mitochondrial impairment to trigger apoptosis and necroptosis in Rhabdomyosarcoma.
TL;DR: The results extended the mechanism of miR-7 antitumor role in rhabdomyosarcoma cancer, and provided potential therapeutic implications for its therapy, and identified mitochondrial impairment mainly contributed to these phenomena.
Journal ArticleDOI
miR-18a counteracts AKT and ERK activation to inhibit the proliferation of pancreatic progenitor cells.
Xuyan Li,Zhenwu Zhang,Zhenwu Zhang,Yunchao Li,Yicheng Zhao,Wenjun Zhai,Lin Yang,Delin Kong,Chunyan Wu,Zhenbao Chen,Chun-Bo Teng +10 more
TL;DR: MiR-18a inhibits proliferation of adult pancreatic progenitor cells through arresting the cell cycle at G1 stage, indicating that miR- 18a plays a role in keeping the adult pancreato-progenitor cells in quiescence.
Journal ArticleDOI
Hippo signaling pathway in liver and pancreas: the potential drug target for tumor therapy.
TL;DR: Several small molecules currently available that can target Hippo-YAP pathway for potential treatment of hepatic and pancreatic cancers are summarized, providing clues for other YAP initiated cancers therapy as well.
Journal ArticleDOI
EGF suppresses the expression of miR-124a in pancreatic β cell lines via ETS2 activation through the MEK and PI3K signaling pathways.
TL;DR: It is demonstrated that EGF could inhibit miR-124a expression in beta cell lines through downstream signaling pathways, including mitogen-activated protein kinase kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) cascades, and that ETS2, as a novel regulator of insulin production, is a potential therapeutic target for diabetes mellitus treatment.